| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 1384 |
| 1 | CYCLOPHOSPHAMIDE | 1250 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 1250 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1250 |
| 4 | DEXAMETHASONE | 1166 |
| 5 | DEXAMETHASONE 1.5 MG | 1166 |
| 6 | VENETOCLAX | 1145 |
| 7 | PREDNISONE | 862 |
| 8 | ALLOPURINOL | 860 |
| 9 | DOXORUBICIN | 824 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FOSAMPRENAVIR CALCIUM | 25 | 0.1923 |
| 1 | RASBURICASE | 356 | 0.1477 |
| 2 | TAGRAXOFUSP | 26 | 0.0500 |
| 3 | FLOXURIDINE | 6 | 0.0364 |
| 4 | PENTOSTATIN | 30 | 0.0286 |
| 5 | VENETOCLAX | 1145 | 0.0187 |
| 6 | ETHIODIZED OIL | 22 | 0.0172 |
| 7 | ROMIDEPSIN | 13 | 0.0171 |
| 8 | CHLORAMBUCIL | 60 | 0.0153 |
| 9 | CLEMASTINE FUMARATE | 19 | 0.0140 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 2435 |
| 1 | Alkylating Drug [EPC] | 1469 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 1441 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 1357 |
| 4 | BCL-2 Inhibitor [EPC] | 1145 |
| 5 | Platinum-based Drug [EPC] | 1116 |
| 6 | Xanthine Oxidase Inhibitor [EPC] | 985 |
| 7 | Topoisomerase Inhibitor [EPC] | 775 |
| 8 | Kinase Inhibitor [EPC] | 680 |
| 9 | Proteasome Inhibitor [EPC] | 653 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD123 Interaction [EPC] | 26 | 0.0500 |
| 1 | Human Immunoglobulin [EPC] | 1 | 0.0196 |
| 2 | BCL-2 Inhibitor [EPC] | 1145 | 0.0187 |
| 3 | CD22-directed Immunoconjugate [EPC] | 33 | 0.0112 |
| 4 | Anthracycline Topoisomerase Inhibitor [EPC] | 25 | 0.0107 |
| 5 | Topoisomerase Inhibitor [EPC] | 775 | 0.0101 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 36 | 0.0099 |
| 7 | CD33-directed Immunoconjugate [EPC] | 33 | 0.0091 |
| 8 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 11 | 0.0085 |
| 9 | CD38-directed Cytolytic Antibody [EPC] | 42 | 0.0075 |